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Abstract
In vivo evaluation of commercially available 
gel-type polyethylene glycol membrane for carrier of 
recombinant human bone morphogenetic protein-2
Ji Woong Jang, D.D.S., M.S.D.
Department of Dentistry
The Graduate School, Yonsei University
(Directed by Professor Kyoo-Sung Cho, D.D.S., M.S.D., PhD.)
Objective: This study evaluated a commercially available, 3-dimensional gel-type 
polyethylene glycol (PEG) membrane as a carrier for rhBMP-2 using a rat calvarial 
defect model. Another gel-type carrier, fibrin-fibronectin system (FFS) was used as a 
positive control.
Material and Methods: Critical-sized defects were made in rat calvarium, which 
were then allocated to ten groups comprising two healing periods and biomaterial 
conditions: (1) sham control, (2) FFS only, (3) FFS/BMP-2, (4) PEG only, (5) 
PEG/BMP-2. Radiographic and histologic analyses were performed at 2 and 8 weeks 
after surgery.
vResults: After 2 weeks, some parts of FFS were biodegraded and extensive cellular 
infiltration was observed at sites that received FFS or FFS/BMP-2. PEG membrane 
retained its augmented volume without cellular infiltration at sites that received PEG 
or PEG/BMP-2. After 8 weeks, FFS was completely degraded and replaced by new 
bone and connective tissues. On the other hand, the volume of residual PEG was 
similar to that at 2 weeks, with slight cellular infiltration. In particular, there was 
progressed bone regeneration around micro-cracks and resorbed outer surface in the 
PEG/BMP-2. Although PEG/BMP-2 showed increased area and percentage of new 
bone, there is no statistical significance after 2 weeks and 8 weeks in 
histomorphometric analyses. However, the appearance of the healing differed (with 
new bone formation along microcracks in PEG/BMP-2), and further studies with 
longer healing periods are needed to draw conclusions about clinical applications.  
Conclusion: Evidences of mechanical stability and new bone formation along micro-
cracks within PEG/BMP-2 might support PEG membrane as a candidate carrier 
material for rhBMP-2. 
KEYWORDS: bone morphogenetic protein-2, polyethylene glycols, bone 
regeneration, bone substitutes, hydrogel, fibrin
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I. Introduction
Various barrier membranes have been developed and used for periodontal and 
bone regeneration during the past 3 decades. Among these, expanded 
polytetrafluoroethylene (ePTFE) membrane was recommended as the gold standard 
until its commercial use was discontinued. Even though ePTFE membrane could 
produce more predictable bone regeneration in many cases, it has disappeared from 
dental use due to manageability difficulties and the necessity for additional surgery to 
2remove the membrane. In addition, membrane exposure can frequently occur in cases 
using nonresorbable membranes, and this complication may be associated with the 
loss of soft tissue and bacterial infection at the augmented site.
Resorbable collagen membrane is the most widely used barrier membrane for 
bone regeneration in dental applications, due to its favorable clinical manageability. 
Moreover, previous studies have demonstrated that collagen and ePTFE membranes 
exhibit comparable suitability for guided bone regeneration,(Coulthard et al., 2003; 
Esposito et al., 2006) which has lead to nonresorbable membrane being replaced by 
resorbable membrane.(Buser et al., 1993; Hammerle and Karring, 1998) However, 
these studies were restricted to favorable defect types such as dehiscence, fenestration, 
and other horizontal defects. The insufficient mechanical stability of a resorbable 
membrane can make it difficult to apply to unfavorable types of defects such as 
vertical ridge deficiency. Since ePTFE membranes are no longer commercially 
available, the use of various other treatment options has been suggested, such as 
allogenous/synthetic bone block, titanium mesh, and a newly developed gel-type 
membrane. 
A gel-type membrane was developed based on hydrogel technology using a 
complex of polyethylene glycols (PEGs), which can be degraded by water with a 
minimal adverse response. Previous studies found that the hydrolysis of a gel-type 
membrane is a significantly slower process than the biodegradation of resorbable 
collagen membrane, with most of the morphologic structure being maintained over a
32-month period.(Herten et al., 2009) In subcutaneous transplantation it was 
demonstrated that cells could penetrate the gel-type membrane even after 
4 months.(Wechsler et al., 2008) Randomized clinical trials using this gel-type and 
collagen membranes revealed comparably successful bone formation in the 
experimental and control groups, and a significantly reduced time for membrane 
application due to its easy clinical manageability.(Jung et al., 2009a; Ramel et al., 
2012) These properties of long-term mechanical stability and favorable clinical 
manageability have made the gel-type membrane a candidate material for use in 
guided bone regeneration with vertical augmentation. However, high rates (up to 
60%) of clinical complications occurred in the vertically augmented sites, such as 
delayed healing, wound dehiscence, and limited bone regeneration within the grafted 
area, although several case reports showed successful regeneration of alveolar
ridge.(Esposito et al., 2009) These complications can even occur in vertical 
augmentation cases using an ePTFE membrane or autogenous block bone graft due to 
the restricted healing potential at the recipient site. 
The above-mentioned considerations led the present authors to hypothesize that 
combining clinical technology with recombinant human bone morphogenetic protein-
2 (rhBMP-2) can enhance bone regeneration within the protected site by the use of a 
gel-type membrane. The specific aim of this study was to evaluate a commercially 
available gel-type PEG membrane as a carrier for rhBMP-2 using a rat calvarial 
defect model and with healing periods of 2 and 8 weeks.
4              II. Materials and Methods
1. Animals
One hundred male Sprague-Dawley rats (body weight 200–300 g) were used in 
ten groups, covering five types of materials and two healing periods. Animals were 
kept in plastic cages in a room at an ambient temperature of 21°C with ad libitum 
access to water and a standard laboratory pellet diet. Animal selection, care, and the 
surgical protocol were approved by the Institutional Animal Care and Use committee 
at Yonsei Medical Center, Seoul, Korea (2011-0322).
2. Materials
Gel-type membrane: Commercially available, synthetic PEG membrane 
(MembraGel®, Straumann, Basel, Switzerland) was used as the gel-type membrane. 
Two sterile PEG components were packed in separate syringes; this allowed the 
membrane to be applied in a liquid state, with mixing of the components resulting in 
hydrogel solidification shortly thereafter.
Fibrin-fibronectin system: A commercially available fibrin-fibronectin sealing 
system (FFS; Tisseel®, Immuno, Vienna, Austria) was used as a positive control for 
the gel-type carrier. In our previous study, this FFS carrying rhBMP-2 induced bone 
formation and produced significantly enhanced bone healing within critically sized 
5calvarial defects. (Han et al., 2005)
rhBMP-2: A commercial institute (Korea Bone Bank, Seoul, Korea) provided 
rhBMP-2 that had been expressed by Chinese hamster ovary cells, and this was 
reconstituted and diluted in a buffer solution to a concentration of 0.05 mg/ml.
3. Study design
Surgically produced, critically sized, rat calvarial defects were grafted with 
biomaterials according to the experimental design. Experimental groups were 
allocated to ten groups covering two healing periods (2 and 8 weeks) and five 
biomaterial conditions as follows:
- Sham control: standardized calvarial defect produced but no grafted 
biomaterials used.
- FFS: calvarial defect grafted with a prefabricated, standardized disc comprising 
FFS only.
- FFS/BMP-2: calvarial defect grafted with a disc comprising an FFS mixture 
containing 5 mg of rhBMP-2.
- PEG: calvarial defect grafted with a prefabricated, standardized disc 
comprising gel-type PEG membrane only.
- PEG/BMP-2: calvarial defect grafted with a disc comprising a PEG membrane 
mixture containing 5 mg of rhBMP-2.
64. Prefabrication of FFS and PEG discs
The four types of discs were prefabricated according a previously described 
protocol.(Han et al., 2005) Briefly, a gel-type FFS and PEG membrane was made by 
mixing each solution set according to the manufacturer’s recommendation. rhBMP-2 
solution (100 ml) at a concentration of 0.05 mg/ml was then added to the FFS and 
PEG mixture. The mixture was injected into a custom-made circular mold with a 
diameter of 8 mm, which yielded standardized 8-mm-diameter discs after 
solidification.
5. Surgical procedures
The animals were anesthesized by an intramuscular injection (5 mg/kg body 
weight) of ketamine hydrochloride (Ketalar®, Yuhan, Seoul, Korea) and xylazine 
(Rompun®, Bayer Korea, Seoul, Korea). The surgical site was shaved and disinfected 
with iodine. A linear incision was made midsagitally and a full-thickness flap was 
reflected. A standardized, circular, transosseous defect with a diameter of 8 mm was 
prepared on the calvarium using a trephine drill (3i Implant Innovation, Palm Beach 
Gardens, FL, USA). The trephined calvarial disk was removed carefully to avoid 
injury to the brain, and the treatments were then applied to the defect area according 
to the group allocations. All surgical sites were sutured with 4-0 Monosyn® (glyconate 
absorbable monofilament, B-Braun, Aesculap, PA, USA) for primary wound closure. 
The animals were sacrificed by CO2 suffocation at either 2 or 8 weeks after surgery.
76. Micro-computed tomography
The specimens were fixed in 10% neutralized-buffered formalin for 10 days and 
scanned using a micro-computed tomography (micro-CT) system (Skyscan® 1072, 
Skyscan, Aartselaar, Belgium) at a resolution of 35 μm (100 kV and 100 μA) before 
processing for the histology analysis. The site of interest was reconstructed and 
analyzed using OnDemand 3D® software (Cybermed, Seoul, Korea). Mineralized 
tissues were distinguished based on a previously described threshold of 275 mg cm–
3.(Aghaloo et al., 2006) Segmentation of mineralized tissue from the total augmented 
area and exclusion of native calvarial bone were performed. Segmented newly formed 
mineralized tissue is coded in red in Fig. 1. The total augmented volume and newly 
formed mineralized tissue volume were measured for quantitative analysis. The 
degree of defect resolution was quantified as the percentage of newly formed 
mineralized tissue volume relative to the calvarial defect volume.
7. Histology analysis and histometric measurements
The specimens were decalcified in 5% formic acid for 14 days, and then 
embedded in paraffin. Serial 5-μm-thick sections were prepared through the center of 
the calvarial defects. The two central-most sections were selected from each block 
and stained with Masson’s trichrome. Each slide was examined, and digital images 
were obtained using a light microscope equipped with a digital camera (BX50, 
Olympus, Tokyo, Japan). Computer-assisted histometric measurements were carried 
8out using an automated image analysis system (Image-Pro Plus, Media Cybernetics, 
Silver Spring, MD, USA). The areas and percentages of new bone, residual material, 
and fibrovascular tissue were measured. The augmented area bordered by an outline 
of grafted biomaterials including newly formed bone was measured, and residual 
biomaterial or newly formed bone was measured separately within the augmented 
area. The amount of fibrovascular tissue was calculated by subtracting the area of 
newly formed bone and residual biomaterials from the augmented area. The 
proportion of each component within the augmented area was calculated. The 
measured parameters and the calculation methods are illustrated in Fig. 1.
8. Statistical analysis
Statistical software was used to analyze the results from micro-CT and 
histomorphometry analyses (SPSS 15.0, SPSS, Chicago, IL). One-way ANOVA and 
the post-hoc Scheffe test were used to analyze the differences between groups at each 
healing period. The independent t-test was carried out to evaluate the effect of time. 
The cutoff for statistical significance was set at p=0.05.
9                   III. RESULTS
1. Clinical Findings
The entire study period passed uneventfully for all animals, with no 
postoperative infections and normal wound healing observed during the experimental 
period.
2. Histology and radiography findings
Two-week healing period: The histology and radiography results for the sham 
controls showed that a very small amount of new bone had filled the defect margin 
and that most of the defect contained loose connective tissue (Figs. 2 and 3). In both 
the PEG and PEG/BMP-2 groups, after 2 weeks of healing, the PEG membrane 
maintained the augmented area and there was no inflammatory reaction. Cell 
infiltration within the PEG shell and the resorption process of biomaterials were 
barely detectable, and the cell-occlusion property persisted. Some fragmentation was 
detected within the inner part of the PEG membrane during histology analysis. There 
was a limited amount of newly formed bone at the periphery of the defect toward the 
calvarium. In particular, new bone ingrowth in clear space between the PEG 
membrane and original bone was observed in the PEG/BMP-2 group (Fig. 4). In 
contrast to the PEG membrane, the adapted FFS at sites that received FFS or 
FFS/BMP-2 exhibited considerable biodegradation, and extensive cell infiltration was 
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observed. The defect contained a small amount of residual FFS, fibrovascular tissue, 
and new bone. Although there was a small amount of new bone at the periphery of the 
defect in the FFS-only group, the use of FFS/BMP-2 increased the amount of newly 
formed woven bone at the defect margin (Fig. 5). The radiography findings were 
similar to the histology findings. The filling of the radiopaque defect was slightly 
increased in the PEG/BMP-2 than the PEG-only group, but both PEG and PEG/BMP-
2 produced small degrees of defect filling. The radiography images indicated that 
FFS/BMP-2 produced enhanced radiodense tissues compared to the other groups (Fig. 
2). 
Eight-week healing period: After 8 weeks of healing, the dimensions of the adapted 
PEG membrane were well maintained, and slight cell invasion was detectable in the 
groups that received PEG or PEG/BMP-2. Outline irregularities and slight resorption 
of the outer surface were evident. While bone regeneration had slightly increased and 
most of the defect contained residual PEG membrane and fibrous tissues in the PEG-
only group, progressed bone regeneration was detected at microcracks and at the 
resorbed outer surface area in the PEG/BMP-2 group (Fig. 4). Microcracks in the 
PEG shell facilitated cell invasion and subsequent matrix remodeling.(Wechsler et al., 
2008) rhBMP-2 released around the microcracks induced effective new bone 
formation at sites that received PEG/BMP-2. Moreover, rhBMP-2 around the 
resorbed outer surface of PEG membrane also enhanced the formation of new bone. 
Micro-CT revealed that the defect filling was still restricted in the PEG-only group, 
whereas radiopaque defect filling was increased around the defect borders in the 
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PEG/BMP-2 group (Fig. 2). The adapted FFS was completely degraded and had been 
replaced by new bone or connective tissues at sites that received FFS or FFS/BMP-2. 
There was a small amount of new bone formation toward the center of the defect at 
sites that received FFS only, whereas increased amounts of mature lamellar bone and 
bone marrow were seen throughout the implantation site in the FFS/BMP-2 group 
(Fig. 5). The radiographic images showed marked radiopacity, with the defect being 
almost completed covered with mineralized tissues in the FFS/BMP-2 group. The 
FFS-only group still showed restricted radiopaque defect filling (Fig. 2). In the sham 
controls, as at 2 weeks postsurgery, there was a minimal amount of new bone at the 
defect margin and most of the defect still contained loose connective tissue (Fig. 3).
3. Histomorphometry measurements and quantitative           
micro-CT analyses.
At sites that received PEG or PEG/BMP-2, the area and percentage of residual 
PEG were maintained, and there were no significant differences between 2 and 8 
weeks. On the other hand, at sites that received FFS or FFS/BMP-2, the adapted FFS 
was quite degraded after 2 weeks, and there was no residual FFS after 8 weeks (Table 
1). The percentage and area of new bone were significantly greater for FFS/BMP-2 
than for the other groups after 2 and 8 weeks. Although sites with PEG/BMP-2 
showed increased area and percentage of new bone, the differences were not 
statistically significant except relative to sham surgery after 2 and 8 weeks (Table 1). 
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The quantitative micro-CT results were similar to histomorphometry measurements. 
The mineralized volume and defect resolution were significantly greater in the 
FFS/BMP-2 group than in the other groups. On the other hand, PEG/BMP-2 did not 
induce significantly increased mineralized volume or defect resolution (Table 2).
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IV. DISCUSSION
This study evaluated the use of a gel-type PEG membrane as a carrier for 
rhBMP-2, with the specific objective of radiographically and histologically observing 
the bone healing process within rat calvarial defects grafted with PEG membrane 
carrying rhBMP-2, in comparison to the use of FFS with rhBMP-2. To focus on the 
osteoinductive effects of rhBMP-2 carried by a gel-type PEG membrane, no other 
bone substitutes were included in this study, and FFS was used for a positive control 
carrier based on previous results.(Hong et al., 2006) However, little bone formation 
was observed within defects grafted with either PEG/BMP-2 or PEG irrespective of 
the healing period (2 or 8 weeks) and despite extensive augmentation based on the 
volume of the PEG membrane. In contrast, bone formation was induced at sites 
grafted with FFS/BMP-2, and the defect was almost complete covered by newly 
formed bone with complete degradation of biomaterials after 8 weeks of healing. This 
is consistent with the results of a previous study that evaluated FFS as a carrier for 
rhBMP-2 in the same animal model.(Han et al., 2005)
At 2 weeks after surgery, residual biomaterials could be observed at all 
experimental sites, but with the appearance differing according to the grafted 
biomaterials (i.e., FFS and PEG membrane). While only small remnants of FFS 
remained and extensive cellular infiltration could be found around/within residual 
biomaterials at sites that received FFS or FFS/BMP-2, most of the augmented volume 
of PEG membrane remained, with limited evidence of cellular infiltration or 
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resorption processes of biomaterials at sites that received PEG or PEG/BMP-2. Even 
at the 8-week healing period, the volume of residual PEG membrane was similar to 
that after 2 weeks, and the membranes separated the defect area from the covering 
mucocutaneous flap with small amounts of cellular infiltration into the membrane. 
These observations may be related to cell occlusiveness and mechanical stability as 
an ideal property of a barrier membrane, and these properties might also explain 
previous clinical results.(Jung et al., 2009b; Jung et al., 2006; Thoma et al., 2009; 
Thoma et al., 2011)
Previous studies have found that the use of a PEG matrix delivering rhBMP-2 
accelerated or enhanced bone regeneration in various animal defect models.(Hanseler 
et al., 2012; Jung et al., 2008; Wehrhan et al., 2012; Wen et al., 2011) However, in the 
present results, the use of a PEG membrane carrying rhBMP-2 did not enhance bone 
healing within critically sized rat cavarial defects compared to the healing at sites that 
received PEG membrane only. This difference between the studies might be due to 
the methods used to apply the PEG membrane carrier—while the previous studies 
used a mixture of PEG matrix and bone substitute particles, the present study used a 
PEG membrane only as a carrier of rhBMP-2. rhBMP-2 that is entrapped within the 
PEG membrane after gelation cannot participate in the in vivo healing processes, and 
so any effects of rhBMP-2 carried by the PEG membrane would depend on the 
presence of degradation or mechanical cracking.(Lutolf et al., 2003) This idea is 
supported by the present results for the 8-week samples, in which new bone formation 
was evident along microcracks within the PEG membrane or on resorbed outer 
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surfaces at sites that received PEG/BMP-2, whereas only fibrous tissue formed 
around and within the biomaterials at sites that received PEG membrane only. In the 
previous studies that used mixtures of PEG matrix and bone substitutes, mechanical 
stability would have been significantly decreased in the presence of increased 
interfaces between heterogeneous biomaterials, and these could influence the release 
of rhBMP-2 from the PEG matrix. These features could finally produce clinical and 
histologic enhancements of bone regeneration within the defects even for the same 
observational period. Considering these previous results, rhBMP-2 carried by PEG 
membrane can also be expected to enhance bone formation over a longer healing 
period, with greater biodegradation of the biomaterials. The present authors 
hypothesized that clinical application of rhBMP-2 carried by PEG membrane can 
enhance bone regeneration within the augmented area in guided bone regeneration. 
This study therefore histologically evaluated the osteoinductivity when using a gel-
type PEG membrane containing rhBMP-2. While the histomorphometric results 
indicated that the use of PEG/BMP-2 failed to enhance bone formation after 2 and 
8 weeks of healing, evidences of mechanical stability and new bone formation along 
micro-cracks within PEG/BMP-2 might support PEG membrane as a candidate 
carrier material for rhBMP-2. However, further studies with longer healing periods 
are needed to draw conclusions about clinical applications. In addition, various 
methodologies for applying PEG membrane should be developed and studied in order 
to control the degradation of biomaterials.
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Figure Legends
Figure 1. Schematic diagrams of the methods used for histomorphometry 
measurements (a) and quantitative micro-CT analyses (b). The histology diagram 
shows defect margins, in which the augmented area (light gray) with residual 
biomaterials, newly formed bone (brown), and fibrovascular tissues (blue) were 
measured. The augmented area bordered by an outline of grafted biomaterials 
including newly formed bone was measured, and residual biomaterial or newly 
formed bone was measured separately within the augmented area. The amount of 
fibrovascular tissue was calculated by subtracting the area of newly formed bone and 
residual biomaterials from the augmented area. In micro-CT analysis, segmentation of 
mineralized tissue from the total augmented area and exclusion of native calvarial 
bone were performed. Segmented newly formed mineralized tissue is indicated in red.
Figure 2. Three-dimensionally reconstructed micro-CT views demonstrating marked 
radiopaque defect filling in the FFS/BMP-2 group compared to the other groups, 
regardless of the experimental period. The use of PEG/BMP-2 produced a larger 
mineralized volume than in the PEG-only group, but both groups showed restricted 
radiopaque mineralized tissue after 2 and 8 weeks.
Figure 3. Overview of histology results after 2 and 8 weeks. After 2 weeks, there was 
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no histologically detected cell invasion at sites that received PEG or PEG/BMP-2, and 
the PEG membrane was well maintained. In contrast, at sites that received FFS or 
FFS/BMP-2, the adapted FFS was quite biodegraded and cell infiltration was 
observed. After 8 weeks, the adapted FFS was completely degraded and had been 
replaced by new bone and connective tissues. However, the dimensions of the PEG 
membrane were still maintained and there was a small amount of cellular infiltration. 
In particular, there was enhanced bone regeneration around microcracks and a 
resorbed outer surface in the PEG/BMP-2 group. The PEG-only group showed 
fibrovascular tissue formation around areas with microcracks. (Masson trichrome 
stain, original magnification ´40.)
Figure 4. Representative photomicrographs of the PEG (a, c) and PEG/BMP-2 (b, d) 
groups. After 2 weeks, the PEG membrane was maintained in the augmented area and 
intact with an absence of inflammation. Cell infiltration within the PEG membrane 
was barely detectable, and the cell-occlusion property persisted (a, b). In particular, 
new bone ingrowth in clear space between PEG membrane and original bone was 
observed (b), whereas there was a restricted amount of new bone at the periphery of 
the defect (a). After 8 weeks, the augmented area was still maintained and the PEG 
membranes were able to provide sufficient physical strength. Irregularities formed in 
the outline, and slight cell invasion was detectable (c, d). Progressed bone 
regeneration was detected at the defect periphery, center area, and resorbed outer 
surface (d). This could reflect that microcracking in the PEG shell facilitated cell 
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invasion and subsequent matrix remodeling. rhBMP-2 that is entrapped within the 
PEG membrane after gelation cannot participate in the healing process. However, 
rhBMP-2 released from around microcracks can induce new bone formation. There 
was limited bone regeneration and most of the defect still contained PEG membrane 
and fibrovascular tissue (c). ( = new bone; Masson trichrome stain, low 
magnification ´40; high magnification ´100.)
Figure 5. Representative photomicrographs of the FFS (a, c) and FFS/BMP-2 (b, d) 
groups. Only small remnants of FFS remained after 2 weeks, and extensive cellular 
infiltration could be found around residual biomaterials (a, b). Newly formed woven 
bone was deposited at the defect margin (b), whereas there was a restricted amount of 
new bone (a). After 8 weeks the adapted FFS had completely degraded and was 
replaced by new bone and connective tissues (c, d). Mature lamellar bone and bone 
marrow were evident throughout (d), whereas newly formed bone remained limited 
(c). (    = new bone, = bone marrow; Masson trichrome stain, low magnification 
´40; high magnification ´100.)
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Tables
Table I. Composition of total augmented area (mm2; and proportion; %) in
histomorphometric analysis. (mean ± SD values; n = 10 )
Sham
Surgery
FFS
FFS/
BMP-2
PEG
PEG/
BMP-2
Augmented
area 
2 weeks
0.95 ± 0.31
(100)
11.61 ± 2.27 a
(100)
12.85 ± 1.85 a
(100)
34.08 ± 3.82 abc
(100)
37.58 ± 3.48 abc
(100)
  
8 weeks
0.76±0.25
(100)
11.54 ± 3.20 a
(100)
10.80 ± 3.58 a
(100)
30.22 ± 6.28 abc
(100)
27.75 ± 5.44 *abc
(100)
New bone 
2 weeks
0.09 ± 0.05
(11.53 ± 10.21)
1.71 ± 0.88 a
(16.67 ± 13.48)
3.76 ± 1.37 abd
(30.62± 15.07 abde )
1.53 ± 0.90 a
(4.43 ± 2.23)
2.61 ± 1.14 a
(6.86 ± 2.86)
8 weeks 
0.19 ± 0.08 *
(25.29 ± 7.02 *)
3.98 ± 0.91 *a
(36.50± 11.60 *de)
6.23 ± 1.93 *abde
(64.80± 24.24*abde)
2.94 ± 0.82 *a
(9.77 ± 2.36 *)
3.91 ± 1.12 *a
(15.21 ± 6.53 *)
Residual
material
2 weeks -
4.01 ± 2.40
(33.82 ± 18.86)
4.79 ± 2.41
(36.73 ± 14.2)
23.93 ± 4.40 bc
(69.75 ± 6.37 
bc)
25.54 ± 3.48 bc
(67.39 ± 7.49 bc)
8 weeks -
0.00 *
(0.00 *)
0.00 *
(0.00 *)
20.63 ± 6.19 bc
(67.38 ± 6.31 bc)
14.55 ± 7.31 bc
(50.81 ± 16.31 bc)
Fibrovascular 
tissue
2 weeks
0.86 ± 0.35
(88.47 ± 10.21)
5.89 ± 2.91 a
(49.52 ± 20.12 a)
4.30 ± 2.08 a
(32.65 ± 14.74 a)
8.62 ± 1.80 a
(25.83 ± 7.30 a)
9.43 ± 3.19 a
(25.75 ± 7.55 a)
8 weeks
0.57 ± 0.19
(74.71 ± 7.02)
7.56 ± 3.06 a
(63.50 ± 11.60)
4.57 ± 3.66 a
(36.79 ± 21.53 a)
6.65 ± 1.28 a
(22.84 ± 6.54 a)
9.29 ± 3.07 a
(33.99 ± 12.51a)
aSignificant difference from sham control group (P < .05)
bSignificant difference from FFS group (P < .05)
cSignificant difference from FFS/BMP-2 group (P < .05)
dSignificant difference from PEG group (P < .05)
eSignificant difference from PEG/BMP-2 group (P < .05)
*Significant difference between at 2 and 8 weeks postsurgery (P < .05)
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Table II. Results of radiographic analyses using micro-CT 
(mean ± SD values; n = 10)
Sham
Surgery
FFS
FFS/
BMP-2
PEG
PEG/
BMP-2
Augmented
volume
(mm3)
2 weeks 53.57 ± 13.22 92.53 ± 20.28 a 86.07 ± 19.71 a 120.54 ± 25.52 ac 136.33 ± 21.60 abc
8 weeks 41.56 ± 7.65 * 80.41 ± 13.95 a 81.96 ± 20.86 a 112.28 ± 15.05 abc 110.92± 11.77*abc
Mineralized
volume
(mm3)
2 weeks 2.32 ± 0.43 4.52 ± 1.72 14.24 ± 3.44 abde 3.84 ± 1.29 6.97 ± 3.34 a
8 weeks 3.46 ± 0.36 * 7.72 ± 1.56 * 23.63 ± 10.58 *abde 4.64 ± 1.12 * 8.38 ± 5.81 *
Defect
resolution
(%)
2 weeks 9.67 ± 1.57 16.65 ± 7.02 a 51.19 ± 6.28 abde 11.75 ± 3.42 22.20 ± 9.45 a
8 weeks
10.53 ± 1.84 24.87 ± 4.88 ad 65.07 ± 24.59 abde 14.12 ± 3.93 21.86 ± 11.06 ad
aSignificant difference from sham control group (P < .05)
bSignificant difference from FFS group (P < .05)
cSignificant difference from FFS/BMP-2 group (P < .05)
dSignificant difference from PEG group (P < .05)
eSignificant difference from PEG/BMP-2 group (P < .05)
*Significant difference between at 2 and 8 weeks postsurgery (P < .05)
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국문요약
골형성 유도 단백질의 전달체로서
폴리에틸렌글리콜 막
(gel-type polyethylene glycol membrane)의 평가
< 지도교수 조규성 >
연세대학교 대학원 치의학과
장 지 웅
겔 타입 막은 흡수성 막(resorbable membrane)보다 느리게 분해
(biodegradation)되며 2달 이상 그 형태학적 구조를 유지할 수 있다. 뿐만
아니라 시술 부위에 빠르게 적용할 수 있는 임상적 편리함때문에 성공적인
골재생을 보이는 것으로 알려져 있다. 이 연구의 목적은 시판되어 임상에
사용되고 있는 겔 타입 폴리에틸렌글리콜 막을 골형성유도단백질(bone 
morphogenetic protein)의 전달체로서 그 효과를 평가하는 것이다. 
FFS(fibrin-fibronectin system)가 양성대조군으로 사용되었다.
총 100마리의 백서를 5군으로 나누어 실험을 시행하였으며, 모든 동
물에서 두개골 부위 직경 8mm의 골결손부를 형성하였다. 각각의 군은 다
음과 같으며 (1) sham-surgery control, (2) FFS only, (3) FFS plus BMP-
2, (4) PEG only, (5) PEG plus BMP-2  2주와 8주의 치유 기간 후
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희생하여 조직학적 및 조직계측학적 정량분석을 시행하였다.                                                                                 
2주 후 FFS only 및 FFS plus BMP-2 군에서 FFS의 일부분이 분
해되고 광범위한 세포 침윤이 관찰된다. PEG only 및 PEG plus BMP-2 
군은 거상된 부피가 잘 유지되고 있으며 세포 침윤은 거의 관찰되지 않았
다. 8주 후 FFS only 및 FFS plus BMP-2군에서는 잔존 FFS가 거의 분해
되고 신생골로 대체된 반면 PEG 그룹에서는 그 부피가 2주와 거의 비슷
하고 약간의 세포 침윤이 관찰되었다. 특히 PEG plus BMP-2 그룹에서 미
세균열(micro-crack) 및 resorbed outer surface에서 많은 신생골 재생을
보였음에도 불구하고 통계학적 유의성은 관찰되지 않았다. 그러나 치유되
는 양상이 다르므로 (micro-crack 주위로 신생골 형성)  정확한 평가를
위해 더 긴 치유기간에서 재평가가 필요하다.
PEG plus BMP-2는 미세균열을 따라 신생골이 잘 형성되었고 충분
한 구조적 안정성을 보였으므로 BMP-2의 전달체로서 효과적으로 사용될
수 있을 것으로 여겨진다.
핵심되는 말: 골 형성 단백질, 폴리에틸렌글리콜, 골 재생, 하이드로겔
